PATH ends September in a difficult position: the stock has shed 32% over the past month to $12.32, a fresh downgrade arrived this week, and short interest near 23% of the float reflects persistent skepticism about the automation software company's recovery story.
The most significant development this week was DA Davidson's downgrade to Underperform with a $10 target, announced Monday. That is the most bearish published target on the Street and marks a genuine shift in tone from a firm that had been neutral. The broader analyst picture has also continued to deteriorate. UBS trimmed its target again, this time to $14 from $15, after already cutting from $19 to $15 the prior week. BMO Capital, Canaccord Genuity, TD Cowen, Truist Securities and RBC Capital all lowered targets earlier in the week, clustering in the $14 to $15 range. No upgrades appeared. Needham remains the lone hold-out at Buy with a $22 target. The consensus mean now rests near $15.50, a gap that once looked like upside but increasingly reflects a list of targets that have not caught up to the pace of the selloff. The bear case, as articulated in available analyst notes, points to multiple compression across the software sector, a dollar-based net revenue retention rate that has slipped to 107%, and limited operating margin expansion ahead. Bulls counter with 14% revenue growth, ARR climbing to $1.85 billion, and a growing cohort of large customers.
Short positioning reinforces the cautious read from analysts, though the structure of the borrow market does not suggest an imminent squeeze. Short interest has edged up roughly 1.4% over the past week to 23% of the free float, approximately 104 million shares. That is a notable level in absolute terms, but it is actually down around 13% from a month ago, when shorts held closer to 120 million shares through late August and early September. Borrow availability is generous: nearly 200% of short interest worth of shares remain available to lend, well above the 52-week trough of 45%. Cost to borrow is a negligible 0.46%, having drifted lower over the past month despite a slight uptick this week. The ORTEX short score of 62 is elevated but has been broadly stable over the past two weeks, suggesting shorts are rebuilding gradually rather than rushing in. Availability this loose and borrow costs this low mean there is no friction constraining new short positions, but equally no squeeze dynamic building.
Options positioning is neutral and remarkably calm given the stock's volatility. The put/call ratio of 0.64 is sitting almost exactly on its 20-day average, with a z-score near zero. That is one of the more surprising readings in the data: despite a 32% one-month decline and a fresh downgrade, options traders are not scrambling for downside protection at unusual rates. The 52-week range on the PCR runs from 0.22 to 0.70, and the current reading is near the top of that band but statistically unremarkable. Valuation multiples have compressed alongside the price, with the price-to-book ratio down more than 1.2 points over the past 30 days to roughly 2.97, and the trailing PE contracting by nearly eight turns to around 13.9.
One element of the ownership picture worth flagging is founder Daniel Dines. He remains the largest individual holder, with roughly 91 million shares, or 17.5% of the company. His 13G filing from February disclosed a stake of 19.2%, and the institutional data shows a reduction of about 11 million shares in the most recent reporting period. The CTO and COO have also been selling under pre-arranged 10b5-1 plans in September, with the CPO and CTO selling around $1.9 million in shares across two transactions. Planned sales under 10b5-1 programmes carry less signal than discretionary ones, but the direction of insider flow is net negative over the past 90 days, with the SEC EDGAR data showing a net reduction of roughly 1.7 million shares worth approximately $27 million. No activist stake is on the 13D register, though Tetragon, which holds around 6.8% and has been building its position, is a name to monitor.
Among closely correlated peers, the week's weakness has been broad but not uniform. ASAN fell 9.4% and CXM dropped 10.4%, both worse than PATH's 7% decline. GWRE fell 5.3%. FRSH and AMPL bucked the trend, each posting modest gains, suggesting selective rather than sector-wide selling. PATH's earnings history adds context: the September 3 print produced a 15.6% next-day drop and a 22.9% five-day slide, and a subsequent event on September 22 resulted in a further 4% one-day decline and 9.3% over five days. The next scheduled earnings date is December 2, 63 days away.
With the downgrade cycle still playing out, short interest edging back toward its recent range, and the next print two months out, the question for PATH will be whether analyst targets converge toward the stock or the stock eventually steadies near current levels and draws fresh buyers into the gap.
See the live data behind this article on ORTEX.
Open PATH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
